REGENXBIO (RGNX) Set to Announce Earnings on Thursday

REGENXBIO (NASDAQ:RGNX) will release its earnings data after the market closes on Thursday, August 1st. Analysts expect REGENXBIO to post earnings of ($1.29) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.10). REGENXBIO had a negative net margin of 299.96% and a negative return on equity of 70.72%. The company had revenue of $15.60 million during the quarter, compared to analysts’ expectations of $23.52 million. During the same quarter last year, the firm posted ($1.53) earnings per share. REGENXBIO’s revenue for the quarter was down 18.3% compared to the same quarter last year. On average, analysts expect REGENXBIO to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

REGENXBIO Stock Performance

Shares of NASDAQ RGNX opened at $14.30 on Wednesday. REGENXBIO has a 52 week low of $10.49 and a 52 week high of $28.80. The business has a 50-day simple moving average of $12.99 and a two-hundred day simple moving average of $16.05.

Analyst Ratings Changes

Several research analysts have commented on the stock. HC Wainwright reissued a “buy” rating and issued a $38.00 price target on shares of REGENXBIO in a report on Thursday, June 20th. The Goldman Sachs Group started coverage on REGENXBIO in a report on Friday, June 7th. They issued a “buy” rating and a $38.00 price target on the stock. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a report on Tuesday, June 18th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $40.00 target price on shares of REGENXBIO in a research report on Friday, April 12th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, REGENXBIO presently has an average rating of “Moderate Buy” and a consensus price target of $38.58.

Insider Activity

In other news, CEO Kenneth T. Mills sold 15,000 shares of the company’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $15.81, for a total value of $237,150.00. Following the sale, the chief executive officer now directly owns 408,035 shares of the company’s stock, valued at approximately $6,451,033.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Curran Simpson sold 9,648 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $15.04, for a total transaction of $145,105.92. Following the completion of the transaction, the chief executive officer now owns 170,137 shares of the company’s stock, valued at approximately $2,558,860.48. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Kenneth T. Mills sold 15,000 shares of REGENXBIO stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $15.81, for a total value of $237,150.00. Following the transaction, the chief executive officer now owns 408,035 shares of the company’s stock, valued at approximately $6,451,033.35. The disclosure for this sale can be found here. Insiders sold a total of 60,079 shares of company stock worth $859,233 in the last quarter. 13.13% of the stock is owned by company insiders.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.